Publication:
Development of an injectable alginate-collagen hydrogel for cardiac delivery of extracellular vesicles.

dc.contributor.authorGil-Cabrerizo, Paula
dc.contributor.authorSaludas, Laura
dc.contributor.authorPrósper, Felipe
dc.contributor.authorAbizanda, Gloria
dc.contributor.authorEchanove-González de Anleo, Miguel
dc.contributor.authorRuiz-Villalba, Adrián
dc.contributor.authorGarbayo, Elisa
dc.contributor.authorBlanco-Prieto, María J
dc.date.accessioned2023-05-03T15:01:44Z
dc.date.available2023-05-03T15:01:44Z
dc.date.issued2022-11-01
dc.description.abstractExtracellular vesicles (EVs) are nanosized particles with attractive therapeutic potential for cardiac repair. However, low retention and stability after systemic administration limit their clinical translation. As an alternative, the combination of EVs with biomaterial-based hydrogels (HGs) is being investigated to increase their exposure in the myocardium and achieve an optimal therapeutic effect. In this study, we developed and characterized a novel injectable in-situ forming HG based on alginate and collagen as a cardiac delivery vehicle for EVs. Different concentrations of alginate and collagen crosslinked with calcium gluconate were tested. Based on injectability studies, 1% alginate, 0.5 mg/mL collagen and 0.25% calcium gluconate HG was selected as the idoneous combination for cardiac administration using catheter-based systems. Rheological examination revealed that the HG possessed an internal gel structure, weak mechanical properties and low viscosity, facilitating an easy administration. In addition, EVs were successfully incorporated and homogeneously distributed in the HG. After administration in a rat model of myocardial infarction, the HG showed long-term retention in the heart and allowed for a sustained release of EVs for at least 7 days. Thus, the combination of HGs and EVs represents a promising therapeutic strategy for myocardial repair. Besides EVs delivery, the developed HG could represent a useful platform for cardiac delivery of multiple therapeutic agents.
dc.identifier.doi10.1016/j.ijpharm.2022.122356
dc.identifier.essn1873-3476
dc.identifier.pmid36332831
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.ijpharm.2022.122356
dc.identifier.urihttp://hdl.handle.net/10668/22271
dc.journal.titleInternational journal of pharmaceutics
dc.journal.titleabbreviationInt J Pharm
dc.language.isoen
dc.organizationCentro Andaluz de Nanomedicina y Biotecnología-BIONAND
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.page.number122356
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAlginate
dc.subjectCollagen
dc.subjectExtracellular vesicles
dc.subjectHydrogel
dc.subjectMyocardial infarction
dc.subject.meshRats
dc.subject.meshAnimals
dc.subject.meshHydrogels
dc.subject.meshAlginates
dc.subject.meshCalcium Gluconate
dc.subject.meshExtracellular Vesicles
dc.subject.meshCollagen
dc.titleDevelopment of an injectable alginate-collagen hydrogel for cardiac delivery of extracellular vesicles.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number629
dspace.entity.typePublication

Files